Nasopharyngeal Diseases, Streptococcal Pneumonia, Vaccination Adverse Event
Conditions
Keywords
Effectiveness, Prevenar, nasopharyngeal carriage, vaccine serotype
Brief summary
A parallel-group, randomized, open-label study will be performed in subjects receiving PCV7 and subjects receiving controlled vaccine Hib vaccine, to claim the efficacy of PCV7 in the prevention of NP carriage of vaccine-serotype S. pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F combined) in 2 to 5 years old healthy Chinese children.
Detailed description
In 2005, clinical trials with PCV7 (Prevenar) were first conducted in China. In the phase 3 study involving Chinese infants, Prevenar was shown to be immunogenic, well tolerated, and safe when given either separately or concomitantly with a diphtheria, tetanus, and acellular pertussis (DTaP) vaccine at 3, 4, and 5 months of age. Controlled clinical trials elsewhere in the world showed the correlation between immunogenicity and disease prevention. In addition to the direct effect of Prevenar, immunization of children has also reduced the incidence of disease in adults. The changes are presumed to be due to reductions in nasopharyngeal carriage of vaccine serotype S. pneumoniae in children who have been vaccinated. The purpose of this study will be to assess the effectiveness of Prevenar vaccination to reduce vaccine serotype (VT) NPC rates in Chinese children aged 2 to 5 years old.
Interventions
BIOLOGICALPCV7 (Pneumococcal 7-Valent Conjugate Vaccine)
injection 0.5 mL, single dose
BIOLOGICALHib Vaccine
Single Dose
Sponsors
Beijing Municipal Health Bureau
Beijing Center for Disease Control and Prevention
Centers for Disease Control and Prevention, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 5 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy children aged 2 to 5 years. 2. Evidence of a personally signed and dated informed consent document indicating that the parent(s) (or legal guardian) has been informed of all pertinent aspects of the study. 3. Subjects and parents / legal guardian/ adult caregiver who are willing and able to comply with scheduled visits, treatment plan, and other study procedures. 4. Available for entire study period and whose parent/legal guardian/adult caregiver can be reached by telephone. 5. Healthy child as determined by medical history, physical examination, and judgment of the investigator.
Exclusion criteria
1. Previous vaccination with licensed or investigational pneumococcal vaccine. 2. Receipt of a full series or catch-up dose of licensed or investigational Hib vaccinations. 3. Contraindication to vaccination with a pneumococcal conjugate vaccine or Hib. 4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection. 5. Known or suspected immune deficiency or suppression including treatment with systemic steroids, anti-metabolites, chemotherapy and immunomodulatory agents. 6. Major known congenital malformation or serious chronic disorder. 7. Malformation or injury of the nasopharynx that makes the procedure of taking a nasopharyngeal swab impossible. 8. Significant neurologic disorder including congenital neurological disease in sibling of the subject or history of seizure including febrile seizure, or significant stable or evolving disorder such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorder. Does not include resolving syndromes due to birth trauma such as Erb's palsy. 9. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies) within 12 weeks prior to enrollment. 10. Participation in another investigational or interventional trial within the 28-day period before enrollment and during the conduct of the study. Participation in purely observational studies is acceptable. 11. Subjects whose parents or legal representative are investigational site staff members or subjects whose parents or legal representative are Pfizer employees directly involved in the conduct of the trial. Temporary
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Carriage Rate of Vaccine-Serotype S. pneumoniae at 180days after vaccination | 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Carriage Rate of vaccine-serotype S. pneumoniae in PCV7 group versus Hib group. | 60 days | — |
| Carriage rate of non-vaccine serotype S. pneumoniae in PCV7 group versus Hib group. | Baseline before vaccination | — |
| Carriage rate of individual serotype S. pneumoniae in PCV7 group and Hib group. | Baseline before vaccination | — |
| Carriage rates of individual serotype S. pneumoniae in PCV7 group and Hib group. | 6 months after vaccination | — |
| Carriage rate of antibiotic resistant S. pneumoniae as a group in PCV7 group and Hib group. | 6 months after vaccination | — |
| Percentage of adverse event related to vaccination in PVC7 group and Hib group. | 6 months after vaccination | — |
| Category of adverse event related to vaccination in PVC7 group and Hib group. | 6 months after vaccination | Adverse effects are classified as referenced from the China Food and Drug Administration's Preventive Vaccines Clinical Study Adverse Effects Assessment Standards. This evaluation of systemic reactions is partially based on standards for classification set by the United States National Institutes of Health and the National Institute of Allergy and Infectious Diseases. |
Countries
China
Outcome results
None listed